← Trials/Trial dossier/NCT04629495
REACH
Active not recruitingPhase 2Rapamycin - Effects on Alzheimer's and Cognitive Health
Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)
Asset
Sirolimus
Listed sites
1
Recruiting sites
-
Enrollment
40
actual
Study population
Alzheimer’s disease, MCI / preclinical Alzheimer’s
Key I/E criteria
•Alzheimer's disease•MMSE 18-30•AD symptomatic therapy: stable
Primary endpoints
•Number of adverse events•Glucose level•Albumin
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Drug assets
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. Both genders and all ethnic groups
2. Ages 55 to 89 years
3. Diagnosis of MCI or AD (Mini Mental Status Examination (MMSE): 18-30; Clinical Dementia Rating Scale (CDR) = 0.5 - 1; California Verbal Learning Test III (CVLT-III) Delayed Recall ≤16% based on age-adjusted norms, clinician approval)
4. Amyloid positivity based on Amyloid PET Imaging
5. Labs: Normal blood cell counts without clinically significant excursions; normal liver and renal function; and glucose control (HbA1c < 6.5%). Fasting lipid panel and prothrombin time/prothrombin time test/international normalized ration (PT/PTT/INR) within normal limits
6. A legally authorized representative (LAR) designated to sign informed consent (if necessary) must attend the Screening visit and accompany the participant to all remaining visits to provide reported outcomes
7. Stable dose of AD medications (Donepezil, rivastigmine, Memantine, galantamine) for at least three months is allowed
Exclusion criteria
1. Diabetes (HBA1c≥6.5% or antidiabetic medications)
2. History of skin ulcers or poor wound healing
3. Current tobacco or illicit drug use or alcohol abuse
4. Use of anti-platelet or anti-coagulant medications other than aspirin
5. Current medications that affect cytochrome 450 3A4 (CYP3A4)
6. Immunosuppressant therapy within the last year
7. Chemotherapy or radiation treatment within the last year
8. Current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities
9. Untreated hypertriglyceridemia (fasting triglycerides < 250 mg/dl)
10. Current or chronic history of pulmonary disease or abnormal pulse oximetry (<90%)
11. Chronic heart failure
12. Pregnancy or lactation
13. Recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack
14. Significant neurological conditions other than AD or MCI
15. Poorly controlled blood pressure (systolic BP>160, diastolic BP>90 mmHg - based on two readings)
16. Active inflammatory, COVID-19, autoimmune, infectious, hepatic, gastrointestinal, malignant, and/or severe mental illness
17. History of, or MRI, or CT positive for, any space occupying lesion, including mass effect or abnormal intracranial pressure, which would indicate contraindications to lumbar puncture
18. Organ transplant recipients
Endpoints (15)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Global cognition
2 endpointsChange in Cognition using preclinical Alzheimer's Cognitive Composite 5 (PACC5)
Time frame:Baseline to 12 months
change from baseline, improvement
Change in Cognition using Clinical Dementia Rating Scale sum of Boxes (CDR-SOB)
Time frame:Baseline to 12 months
Clinical Dementia Rating-Sum of Boxes (CDR-SB)
change from baseline, improvement
Function / daily living
1 endpointChange in Functional status
Time frame:Baseline to 12 months
change from baseline, improvement
Behavior / neuropsychiatric
1 endpointChange in Neuropsychiatric symptoms
Time frame:Baseline to 12 months
change from baseline, improvement
Amyloid biomarkers
1 endpointChange in CSF amyloid beta
Time frame:Baseline to 12 months
change from baseline, improvement
Neuroimaging
2 endpointsChange in cerebral glucose metabolism
Time frame:Baseline to 12 months
change from baseline, improvement
Change in Brain Volumetry
Time frame:Baseline to 12 months
change from baseline, improvement
Safety / tolerability / PK
1 endpointNumber of adverse events
Time frame:Baseline to 12 months
event count, event
Other clinical outcomes
2 endpointsChange in Gait Speed
Time frame:Baseline to 12 months
change from baseline, improvement
Change in Grip Strength
Time frame:Baseline to 12 months
change from baseline, improvement
Other (unclassified)
5 endpointsChange in glucose level
Time frame:Baseline to 12 months
change from baseline, improvement
Change in albumin
Time frame:Baseline to 12 months
change from baseline, improvement
Change in carbon dioxide or bicarbonate (CO2)
Time frame:Baseline to 12 months
change from baseline, improvement
Change in calcium
Time frame:Baseline to 12 months
change from baseline, improvement
Central nervous system penetration of rapamycin
Time frame:Baseline and 12 months
ratio, descriptive
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.